Arcera Life Sciences and Daewoong Expand Strategic Partnership to Bring Enavogliflozin to the Middle EastExpansion builds on successful collaboration across Latin America and reinforces commitment to advancing innovative cardiometabolic therapies across international markets
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer’s DiseaseSeongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively “Arcera”), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease.
